Canaccord Genuity Maintains Buy on Teladoc Health, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity maintains a Buy rating on Teladoc Health but lowers the price target from $25 to $17.

August 01, 2024 | 2:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Canaccord Genuity maintains a Buy rating on Teladoc Health but lowers the price target from $25 to $17.
The Buy rating suggests continued confidence in Teladoc Health's long-term prospects, but the lowered price target indicates a more cautious short-term outlook. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100